SEP 30, 2026 · JOURNAL ARTICLE
Semaglutide for metabolic dysfunction-associated steatotic liver disease in Asian and lean populations
Kosin Medical Journal
The histologic benefits demonstrated in the phase 3 ESSENCE (Effect of Semaglutide in Subjects with Noncirrhotic Nonalcoholic Steatohepatitis) trial have established semaglutide, a